Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01125800
Other study ID # CLDE225X2104
Secondary ID 2010-019348-37
Status Completed
Phase Phase 1/Phase 2
First received May 12, 2010
Last updated February 4, 2016
Start date February 2011
Est. completion date October 2014

Study information

Verified date February 2016
Source Novartis
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationUnited Kingdom: Medicines and Healthcare Products Regulatory AgencyFrance: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)Australia: Department of Health and Ageing Therapeutic Goods AdministrationItaly: Ministry of HealthSpain: Spanish Agency of MedicinesCanada: Health Canada
Study type Interventional

Clinical Trial Summary

Phase I dose-escalation study to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LDE225 given orally on a daily dosing schedule in children with recurrent or refractory medulloblastoma, or other tumors potentially dependent on Hedgehog signaling pathway.

Phase II study is to assess preliminary efficacy in both adult and pediatric patients with recurrent or refractory MB.


Recruitment information / eligibility

Status Completed
Enrollment 76
Est. completion date October 2014
Est. primary completion date October 2014
Accepts healthy volunteers No
Gender Both
Age group 12 Months to 18 Years
Eligibility Inclusion Criteria:

- Phase I - Patients aged =12 months and <18 years, Phase II - Patients =12 months

- Phase I - Histologically confirmed diagnosis of medulloblastoma, rhabdomyosarcoma, neuroblastoma, hepatoblastoma, high grade glioma, or osteosarcoma, that has progressed despite treatment with standard therapies, or for which no standard treatments are available (patients with brainstem gliomas are excluded). Phase II - Histologically confirmed diagnosis of recurrent or relapsed medulloblastoma with at least one measurable lesion.

- Performance Status: Karnofsky =60% for patients >10 yrs, Lansky =50 for patients less than or equal to 10 yrs

- Protocol-defined renal , liver and bone marrow function

- Negative pregnancy test before starting study treatment. If of child bearing potential must use 'highly effective' methods of contraception.

- All patients must consent to provide a tumor sample

Exclusion Criteria:

- Systemic anti-cancer treatment within 2 weeks prior to first dose (6 weeks for nitrosourea, mitomycin and monoclonal antibodies).

- Focal radiotherapy within 4 weeks prior to first dose, or full spinal radiotherapy within 3 months of first dose.

- Unresolved toxicity greater than CTCAE grade 1 from previous anti-cancer therapy or radiotherapy (excluding neurotoxicity, alopecia, ototoxicity, lymphopenia or other specifications in the eligibility criteria for this study), or incomplete recovery from previous surgery, unless agreed by Novartis and the Principal Investigator (PI) and documented.

- Major surgery, serious illness or traumatic injury within 2 weeks of starting study therapy. Patients anticipated to require major surgery within the first 2 cycles of treatment.

- Patients requiring a nasogastric tube for drug administration (G-tubes are permitted)

- Impaired cardiac function

- Pregnant or breast-feeding females

- Impairment of gastrointestinal (GI) function or GI disease

Other protocol-defined inclusion/exclusion criteria may apply

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
LDE225
LDE225/sonidegib capsules were supplied to the Investigators at dose strengths of 50 mg, 100 mg, 200 mg, and 250 mg.

Locations

Country Name City State
Australia Novartis Investigative Site Parkville Victoria
Canada Novartis Investigative Site Toronto Ontario
Canada Novartis Investigative Site Toronto Ontario
France Novartis Investigative Site Paris
France Novartis Investigative Site Villejuif Cedex
Italy Novartis Investigative Site Bologna BO
Italy Novartis Investigative Site Milano MI
Italy Novartis Investigative Site Roma RM
United Kingdom Novartis Investigative Site Newcastle Upon Tyne
United Kingdom Novartis Investigative Site Sutton Surrey
United States Children's Healthcare of Atlanta Childern Hosp - ATL Atlanta Georgia
United States Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. John Hopkins Baltimore Maryland
United States Dana Farber Cancer Institute DFCI (3) Boston Massachusetts
United States Seattle Children's Hospital CPKC412A2114 Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Australia,  Canada,  France,  Italy,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Dose-limiting Toxicities (DLT) in Phase I DLT was defined as an adverse event (AE) or abnormal laboratory value assessed as unrelated to disease, disease progression, intercurrent illness, or concomitant medications. DLT included any grade 3 or 4 clinically-evident toxicity, Hematology: = CTCAE grade 3 neutropenia (ANC <1.0x10^9/L); = CTCAE grade 3 thrombocytopenia (platelets <50x10^9/L); = CTCAE grade 3 anemia (Hgb <80 g/L); Febrile neutropenia (ANC <1x10^9/L, fever ‡ 38.5°C), Renal: = CTCAE grade 3 serum creatinine (>3xULN), Hepatic: = CTCAE grade 3 total bilirubin (>3xULN); = 10xULN ALT elevation; grade 2 total bilirubin (>1.5ULN) together with = grade 3 ALT elevation (>5xULN), Cardiac: = CTCAE grade 3, Other AEs: = CTCAE grade 3 vomiting or nausea despite optimal antiemetic therapy, diarrhea despite optimal antidiarrheal treatment. Baseline, End of dose escalation part (Day 42) Yes
Primary Maximum Tolerated Dose (MTD) of Sonidegib for Prolonged Use MTD was defined as highest dose level for which no more than 1 participant in a dose cohort experienced dose-limiting toxicity (DLT), based on Bayesian logistic regression model (BLRM) employing the escalation with overdose control (EWOC) principle. DLT was defined as an adverse event (AE) or abnormal laboratory value assessed as unrelated to disease, disease progression, intercurrent illness, or concomitant medications.k Baseline, End of dose escalation part (Day 42) No
Primary Percentage of Participants With Objective Response Rate (ORR) by Treatment The tumor response to the sonidegib treatment was measured by ORR. The ORR was defined as the percentage of participants with partial response or complete response as their best overall response. Participants with stable disease, progressive disease tumor assessment were considered as non-responders. Response evaluation criteria was gadolinium chelate-enhanced brain tumor magnetic resonance imaging (Gd-MRI) for Medulloblastoma and central nervous system (CNS) tumors and response evaluation criteria in solid tumors (RECIST) version 1.0 for non-CNS tumors assessed by MRI. Complete Response (CR), Progressive Disease (PD) and Incomplete Response/Stable Disease (SD) were defined as disappearance of all non-target lesions, unequivocal progression of existing non-target lesions and Neither CR nor PD, respectively. Baseline, Day 28 of Cycle 2, End of treatment (Within 14 days of last dose) No
Secondary Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and Death During the Study An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not related to study drug. A SAE was defined as an event which was fatal or life threatening, required or prolonged hospitalization, was significantly or permanently disabling or incapacitating, constituted a congenital anomaly or a birth defect, or encompassed any other clinically significant event that could jeopardize the participant or require medical or surgical intervention to prevent one of the aforementioned outcomes. Treatment related AEs were defined as AEs that were suspected to be related to study treatment as per investigator. On-treatment deaths were deaths which occurred up to 30 days after last date of study treatment. Baseline (start of study treatment) up to End of treatment (Within 14 days of last dose) Yes
Secondary Area Under the Drug Concentration Time Curve From Time Zero to 24 Hours After Dosing (AUC0-24h) of Sonidegib in Phase I AUC(0-24h) was defined as the area under the drug concentration time curve calculated using linear trapezoidal summation from time zero to 24 hours after dosing. Pre-dose, 0.5, 1, 2, 4, 7 hours (± 15 min) post-dose at Day 1 and Day 22 of Cycle 1 No
Secondary Time to Reach Maximum Observed Plasma Concentration (Tmax) of Sonidegib in Phase I Tmax was defined as the time required to reach maximum observed plasma concentration. Tmax was directly determined from the raw plasma concentration time data. Pre-dose, 0.5, 1, 2, 4, 7 hours (± 15 min) post-dose at Day 1 and Day 22 of Cycle 1 No
Secondary Maximum Observed Plasma Concentration (Cmax) of Sonidegib in Phase I Maximum observed plasma concentration following drug administration was calculated from the raw plasma concentration time data. Pre-dose, 0.5, 1, 2, 4, 7 hours (± 15 min) post-dose at Day 1 and Day 22 of Cycle 1 No
Secondary Percentage of Pediatric Participants With Objective Response Rate (ORR) by Hedgehog (Hh) Signaling Pathway Status ORR was determined in the participants with mutations on Hh gene (Hh positive) and the participants without mutations on Hh gene (Hh negative). Baseline, Day 28 of Cycle 2, End of treatment (Within 14 days of last dose) No
Secondary Duration of Response by Treatment Duration of overall response (complete response (CR) or partial response (PR)) was calculated for those participants whose best overall response was CR or PR. The start date was the date of the first documented tumor response (CR or PR) and the end date was the date of the event defined as the first documented progression or death due to underlying cancer or after the same treatment line. If a participant did not have a progression or death, the duration of response was censored at the date of last adequate tumor assessment in that treatment line. Baseline, Day 28 of Cycle 2, End of treatment (Within 14 days of last dose) No
See also
  Status Clinical Trial Phase
Terminated NCT02764151 - First in Patient Study for PF-06840003 in Malignant Gliomas Phase 1
Completed NCT00994071 - A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors Phase 1
Terminated NCT01502605 - Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas Phase 1
Completed NCT02903784 - Neural Basis of Language Processing N/A
Terminated NCT01044966 - A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma Phase 1/Phase 2
Completed NCT00705198 - Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062) N/A
Completed NCT00165360 - Prolonged Daily Temozolomide for Low-Grade Glioma Phase 2
Active, not recruiting NCT03911388 - HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors Phase 1
Terminated NCT00389090 - A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma Phase 2
Completed NCT00154375 - Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Phase 3
Completed NCT00001148 - Detecting Malignant Brain Tumor Cells in the Bloodstream During Surgery to Remove the Tumor N/A
Completed NCT03722355 - Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma Phase 3
Recruiting NCT03975829 - Pediatric Long-Term Follow-up and Rollover Study Phase 4
Recruiting NCT05686798 - Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. Phase 1
Active, not recruiting NCT03739372 - Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma N/A
Recruiting NCT05624736 - Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning
Recruiting NCT05345002 - All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma Phase 2
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Completed NCT00783393 - SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745) Phase 2
Completed NCT03900689 - Social Determinants of Health in Glioblastoma Population